| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers A > Headlines for AnorMED Inc. > News item |
AnorMED's preclinical studies show AMD070 active in HIV patients
By Lisa Kerner
Erie, Pa., March 17 - AnorMED, Inc. said preliminary clinical data on AMD070, an HIV entry inhibitor, shows the drug candidate is active, generally safe and well tolerated in HIV patients.
The data is from XACT, the open-label, dose-finding study funded by AnorMED, according to a company news release.
In the study, up to four cohorts with a total of 12 patients each, will be given twice-daily doses of AMD070 for 10 consecutive days.
Of the eight HIV patients enrolled in the first dose cohort, four had significant reductions in CXCR4 viral load with an average reduction of 1.3 log. As a result, enrollment into the first cohort will be completed and the next dose cohort will be initiated, AnorMED said.
"Given that this is the first dose cohort in our dose-finding study we are very pleased to see such significant activity in 50% of the patients enrolled to date in XACT, with no serious safety concerns to date in any of the patients in this study," director of clinical development Dr. Stephen Becker said in the release.
"Based on these results we hope to move as quickly as possible into our next dose cohort and toward identifying the clinically optimal dose."
AnorMED said it will continue its preclinical safety studies of lead formulations of AMD070 over the next six months, with a phase 2b study to begin by the end of the year. The company will present more detailed activity and safety data from XACT in September 2006.
Vancouver, B.C.-based AnorMED is focused on the discovery, development and commercialization of new therapeutic products in the areas of hematology, HIV and oncology.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.